Tag: #licensing32 results
Cursor launched Composer 2 as enhanced AI coding model via pretraining and RL, but API revealed Kimi K2.5 base, sparking open-source license violation claims. Moonshot AI clarified authorized use via Fireworks AI platform. Not first controversy for Cursor's model origins.
Major gaming companies are phasing out physical media to enforce digital-only distribution, effectively shifting user status from owners to licensees. This move aims to eliminate secondary markets and centralize data control.
BCI startup Neurable is seeking to license its non-invasive mind-reading technology for consumer wearables. The tech focuses on neural data collection with broad consumer applications envisioned by its CEO.
AI advancements have shortened software contracts as customers fear long-term deals will result in obsolete products. This shift reflects the rapid pace of AI innovation outpacing traditional multi-year agreements. Companies are adapting to more flexible, shorter-term licensing models.
Moonshot states Cursor Composer was authorized via Fireworks partnership. Custom license likely permitted non-disclosure of base model. Issue resolved without public contract details.
EVgo has begun building Tesla V4 Superchargers under a licensing agreement. The chargers will appear in Tesla’s navigation app and support both NACS and CCS1 connectors.
Accessory maker Dbrand has canceled its popular 'Companion Cube' case for the Steam Machine after failing to secure intellectual property rights from Valve. Despite 1,000+ hours of engineering and 15,000 pre-orders, the product was pulled due to legal intervention.
Sony has announced that PlayStation customers will lose access to certain purchased movies and shows in September. This incident serves as a stark reminder that digital purchases often function as long-term rentals rather than permanent ownership.
A recent poll on X highlights a shifting trend in the open-source AI community regarding licensing preferences. The discussion reflects ongoing debates about the sustainability and direction of open-weight models.
TNM faces scrutiny over its decision to transfer the development rights of a next-generation tetanus product to Beijing Wantai Biological Pharmacy. The move raises questions about the company's core competitiveness and pipeline depth.